Korea Centers for Disease Control and Prevention (KCDC) chief Jung Eun-kyung explains the details of the corona 19 vaccination at the briefing room of the Centers for Disease Control and Prevention in Osong-eup, Cheongju, Chungbuk on the 15th. News 1
The government has signed an additional contract for a new coronavirus infection (Corona 19) vaccine for 23 million people. It is expected to come in sequentially in the first and second quarters.
The Korea Centers for Disease Control and Prevention announced on the 16th that “we will contract an additional 23 million corona 19 vaccines for a more stable vaccine supply in the first half.”
The disease administration said, “We made an additional purchase contract for 3 million Pfizer vaccines (6 million doses) on the 15th, and the start of supply from the 3rd quarter was advanced to the 1st quarter (end of March).” “We will sign a contract for 20 million doses of NovaVax vaccine (40 million doses).”
The Agency for Disease Control and Prevention said, “As uncertainties in the production and supply of COVID-19 vaccines are increasing worldwide, the quantity of vaccines in the first half is particularly limited.” To prepare for various uncertainties in the supply and demand of these vaccines, 10 million Pfizer vaccines (20 million In addition to the batch), 3 million people (6 million doses) were additionally purchased, and a total of 13 million people (26 million doses) of Pfizer vaccine was purchased.”
In addition, Pfizer vaccine, which is introduced through individual purchases with pharmaceutical companies, rather than Cobax facilitation, was initially scheduled to be introduced from the third quarter, but as a result of early supply negotiations with pharmaceutical companies, 500,000 people (1 million doses) within the first quarter (end of March), 2 It added that 3 million servings (6 million servings) will be supplied in the quarter.
NovaVax (USA) vaccine. Graphic = Reporter Kim Young-ok [email protected]
Currently, the Pfizer vaccine is undergoing approval review by the Ministry of Food and Drug Safety and will be vaccinated from April when the national shipment approval for the vaccine introduced in late March is completed.
The Korea Centers for Disease Control and Prevention (KCDC) held a contract for supplying a vaccine for COVID-19 NovaVax with SK Bioscience at 10 am on the day, and signed a pre-purchase contract for 20 million people (40 million doses).
Chairman James Young will participate in the contract signing ceremony through video connection with NovaVax’s US headquarters, and will discuss cooperation plans for the production and supply of Corona 19 vaccines between the Centers for Disease Control and Prevention, NovaVax, and SK Bioscience.
Earlier, on the 12th, SK Bioscience signed a vaccine technology introduction contract (technology licensee) with NovaVax. In conjunction with this contract, the Korean Disease Administration signed a contract to purchase NovaVax vaccine with SK Bioscience. Domestic production-domestic supply. NovaVax vaccine will be the first case of producing a Corona 19 vaccine in Korea through technology transfer.
The Agency for Disease Control explained, “It will be an opportunity to contribute to securing original technology for vaccine development in Korea and to establish a stable vaccine supply base.”
What is the domestic vaccination schedule for the ’56 million contract’?. Graphic = Reporter Cha Junhong [email protected]
NovaVax vaccine is a synthetic antigen method applied to many vaccines such as influenza and hepatitis B. It is a new platform that is different from the mRNA (Pfizer, Modena) and virus delivery system (AstraZeneca) that the government has purchased. Synthetic antigen vaccine is a method of inducing an immune response by synthesizing an antigenic protein and mixing it with an adjuvant. Refrigerated (2~8℃) storage is possible.
“The government has secured a total of 79 million vaccines (152 million doses) so far, adding 20 million doses (40 million doses) of NovaVax vaccines, which are scheduled to be signed,” said Eun-kyung Chung, director of the Korea Medical Center. In the future, we will continue to work for early supply and rapid vaccination.
Reporter Esther [email protected]